TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total area under the curve (tAUC) of fullness ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of invasive fungal sinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: improved serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improved urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Infarct Volume Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: World Health Organization WHOQOL-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Accuracy on Elicited Production Probes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Comprehension probes (Proportion Looking)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Dose Delivered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Implant Continuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Treatment- emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent contribution of ascorbic acid to urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection of circulating GNA11 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiac Coherence Program Adherence Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma cholesteryl ester transfer protein (CETP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of CETP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with HBV DNA Negativation or Decrease by ≥1 log10 from Baseline at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with HDV RNA Negativation or Decrease by ≥1 log10 from Baseline at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Serum HBsAg Levels at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of anti COVID 19 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease of self-reported depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in self-harming behavior and medical care usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: thumb circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remaining 4 finger circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during debonding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minnesota Rate of Manipulation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semmens Weinstein Monofilament Test (SWMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence Free Interval
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Report Daily Use of E-cigarettes or NRT and no Cigarette Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Have Biochemically-confirmed Abstinence From Cigarette Smoking at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Sustained Alleviation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Olerud Molander Score (OMAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinically significant toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Achieving ACR 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysfunctional Voiding and Incontinence Scoring System (DVAISS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder and Bowel Dysfunction Questionnaire (BBDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Knowledge, Attitude and Practice of Nutrition and Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Physical Activity of the adolescent
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence to prescribed exercise sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Episode of atrial fibrillation (AF) lasting more than 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Insulinogenic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Incremental Glucose Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Control Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic, diastolic, mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cough score during emergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cord blood DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrahepatic concentration of Imdusiran (AB-729)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge, attitudes and practices on tuberculosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of primary safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Net Clinical adverse event (NACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of cfDNA methylation-based model
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cmax of INCBC054707
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of INCB054707
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-∞) of INCB054707
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric analysis of change in treatment zone for acne scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECCA acne grading scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic response to biological therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reversibility of eGFR changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of CIN2+ disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of CIN3+ disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bimanual hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Health Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PI-RADS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate biopsy pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the curve (AUC) of BAY3283142
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration (Cmax) of BAY3283142
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drug Effects Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Biphasic Alcohol Effects Scale (Modified for THC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in The Spielberger State Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Driving Simulation Performance on the Divided Attention Task (DAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of persistent infection, transient infection, and cervical precancerous CIN1+ lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti-HPV 16 and 18 IgG antibody seropositive rates and geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emergent and Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of congenital CMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of peripheral neuropathy ≥ CTCAE grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for risperidone patch-form medicine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confusion matrix accuracy for sagittal views
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confusion matrix accuracy for axial views
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number and proportion of eligible women who had an HPV PCR test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative Range of Motion of Elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival (PFS) Rate at 3-Year
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) Rate at 5-Year
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Experiencing Treatment-related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Re-admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to First Occurrence of Ischemic Stroke
Endpoint domain: Mortality/survival
Primary endpoint: incidence rate of all-cause mortality or hospital readmission
Endpoint domain: Mortality/survival
Primary endpoint: medical cost of medical care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Expression of miR-133a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of miR-208b
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent recruiting participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recovery of kidney functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of BCR::ABL1 IS ≤ 1%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving MaRIA < 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of early liver cancer
Endpoint domain: Mortality/survival
Primary endpoint: Institutional Delivery Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in children's psychosocial symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of Relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unfavorable imaging outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of SSEP neuromonitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Estimate the Maximum Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of study participants retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of questions left blank
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of women who completed all 5 sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Muscle separation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants with HIV-1 RNA ≥ 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Feelings of Shame and Guilt
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in skin carotenoid status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood carotenoid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CRRT circuit clotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnosis of PCOS based on Rotterdam criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True ileal digestibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of officers with permanent threshold shift (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving BICLA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammography screening behavior
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of participants with significant hematomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants with bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early cardiac dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Height status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index (BMI) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body fat percentage status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mass percentage status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood culture positivity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU stay reduction
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Marsh's classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SDMT Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Statistically significant changes in neuroimaging tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Statistically significant changes in immune and inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive Test for Opioids
Endpoint domain: Adverse events/effects
Primary endpoint: IKDC SUBJECTIVE KNEE EVALUATION FORM
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Beck Anxiety Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogue Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BMI-for-age z-score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Beam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiographic changes in periapical area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Best-corrected Visual Acuity (BCVA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Disease Activity in Psoriatic Arthritis (DAPSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of electrocardiogram abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: tpCR rate (ypT0/is ypN0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: family resilience
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: caregiving ability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Isokinetic strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unsolicited adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Fusion Status/Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) Reduction
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Vessel size index (VSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Endocrine parameters (EP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of Ciprofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of endotracheal intubation at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lack of liver injury on histopathologic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Difference in antral area sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of identification of puborectalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of the DNA repair factor XPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of core clock genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of the nucleotide excision repair (NER) system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of DNA damage kinase signaling pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to stop drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IFN-γ concentration after whole blood stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN-γ spot forming cells after stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV-2 T-cell phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Blood Glucose Indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Plasma insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in severity of cancer-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in wound depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of ETD/MEB during compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ViaOne device
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of simvastatin intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with BCR and a positive Fluciclovine PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alignment/Loss of Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate of small intestinal bacterial overgrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abnormal rate of oral cecum transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effective rate of abdominal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Negative conversion rate of small intestinal bacterial overgrowth and oral cecum transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in DUX4-regulated gene expression in muscle biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in a circulating biomarker of FSHD disease biology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status